HealthTree Logo
search more_vert
person Sign In / Create Account
Creating a Risk Profile to Personalize Myeloma Care with Ola Landgren, MD, PhD, University of Miami
Creating a Risk Profile to Personalize Myeloma Care with Ola Landgren, MD, PhD, University of Miami image
HealthTree Podcast for Multiple Myeloma
event Jul 15, 2024 / 11:00AM MDT

Event Description

This show will not be live streamed. You can submit your questions in advance by clicking the button "Notify when available." 

Learn how Ola Landgren, MD, PhD, and his colleagues at the University of Miami are building a sophisticated computational model to predict risk and the optimal treatment path for individual multiple myeloma patients. Learn what he has learned to date and how you can become part of this groundbreaking study. 

Thanks to our episode sponsor, Karyopharm.

Schedule & Agenda

The panelist Jennifer Ahlstrom
11:00 AM
Jennifer Ahlstrom

Welcome, Announcements & Introduction

The panelist C. Ola Landgren, MD, PhD
Discussion with Dr. Ola Landgren
11:05 AM
C. Ola Landgren, MD, PhD



11:50 AM

Audience is able to submit their questions in advance so Dr. Ola Landgren can answer during the discussion.

Speakers & Moderators

The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio
The panelist C. Ola Landgren, MD, PhD
C. Ola Landgren, MD, PhD

C. Ola Landgren, MD, PhD, is Professor of Medicine, Chief of the Myeloma Program, and Leader of the Experimental Program at the University of Miami Sylvester Cancer Center. Read more about his move to Miami here. Dr. Landgren is a pioneer in the drug development and minimal residual disease (MRD) testing in myeloma. In collaboration with colleagues throughout the world, he develops new strategies (including cell-based, molecular-based, and imaging-based) and continues to be a leader of using advanced MRD testing in clinical trials. He is involved in the service’s rational treatment program (small molecule, monoclonal antibody, immune-based) for newly diagnosed, relapsed and refractory myeloma and amyloidosis patients. His research focuses on early drug development, advanced disease monitoring by new minimal residual disease (MRD) assays and biomarkers, and immune-PET to monitor treatment. He also studies mechanism and markers of progression from MGUS/smoldering myeloma to symptomatic multiple myeloma, and the identification of high-risk precursor patients who may be candidates for early treatment. Prior to joining Miami, Dr. Landgren was the Chief Attending Physician of the Myeloma Service at Memorial Sloan Kettering and Professor of Medicine at the Weill Cornell Medical College in New York City and Chief of the Multiple Myeloma Section of the National Cancer Institute in Bethesda, MD. Dr. Landgren received his MD at Karolinska Institute in Stockholm, Sweden; and he has had fellowships at Karolinska University Hospital and the National Cancer Institute. He is a frequent speaker at national and international meetings, and has published more than 400 peer-reviewed papers.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.


Get In Touch With Us




Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube